Research Article
The Huntington disease protein accelerates breast tumour development and metastasis through ErbB2/HER2 signalling
Article first published online: 9 JAN 2013
DOI: 10.1002/emmm.201201546
Copyright © 2013 The Authors. Published by John Wiley and Sons, Ltd on behalf of EMBO
Additional Information
How to Cite
Moreira Sousa, C., McGuire, J. R., Thion, M. S., Gentien, D., de la Grange, P., Tezenas du Montcel, S., Vincent-Salomon, A., Durr, A. and Humbert, S. (2013), The Huntington disease protein accelerates breast tumour development and metastasis through ErbB2/HER2 signalling. EMBO Mol Med, 5: 309–325. doi: 10.1002/emmm.201201546
Publication History
- Issue published online: 4 FEB 2013
- Article first published online: 9 JAN 2013
- Manuscript Accepted: 21 NOV 2012
- Manuscript Revised: 19 NOV 2012
- Manuscript Received: 7 MAY 2012
Funded by
- Funded Access
Keywords:
- breast cancer;
- dynamin;
- huntingtin;
- migration;
- polyglutamine
Abstract
In Huntington disease (HD), polyglutamine expansion in the huntingtin protein causes specific neuronal death. The consequences of the presence of mutant huntingtin in other tissues are less well understood. Here we propose that mutant huntingtin influences breast cancer progression. Indeed, we show that mammary tumours appear earlier in mouse breast cancer models expressing mutant huntingtin as compared to control mice expressing wild-type huntingtin. Tumours bearing mutant huntingtin have a modified gene expression pattern that reflects enhanced aggressiveness with the overexpression of genes favouring invasion and metastasis. In agreement, mutant huntingtin accelerates epithelial to mesenchymal transition and enhances cell motility and invasion. Also, lung metastasis is higher in HD conditions than in control mice. Finally, we report that in HD, the dynamin dependent endocytosis of the ErbB2/HER2 receptor tyrosine kinase is reduced. This leads to its accumulation and to subsequent increases in cell motility and proliferation. Our study may thus have important implications for both cancer and HD.

1757-4684/asset/olbannerleft.jpg?v=1&s=bbd2e0b80f5732e6debc8359b97d6dd36437820d)
1757-4684/asset/olbannerright.jpg?v=1&s=b2a7dc2c527cdc2509c695006f69ea9f80aaab1a)
